Skip to content
DataLookout
Menu

NCT05711615

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 139 versions: 16 with changes below, 34 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Site details revised at 3 of 16 sites
  2. Notable Primary and study completion pushed from Nov 3, 2026 to May 3, 2027
  3. Minor Site details revised at 1 of 16 sites
  4. Minor Site details revised at 1 of 16 sites
  5. Notable Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised at 3 of 16 sites
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Site details revised at 1 of 16 sitesv134
  2. Minor Site details revised at 1 of 16 sitesv133
  3. Minor Site details revised at 1 of 16 sitesv132
  4. Minor Site details revised at 1 of 16 sitesv131
  5. Minor Study sites revised (16)v130
  6. Notable Eligibility criteria shortened, about 36 words
    • Study description shortened, about 126 words
    • Study sites revised (16)
    v128
  1. Notable Primary and study completion pushed from May 3, 2026 to Nov 3, 2026
    • Site details revised at 2 of 16 sites
    v127
  2. Notable Primary and study completion dates: May 3, 2026 to Nov 3, 2026v126
  3. Minor Site details revised at 1 of 16 sitesv115
  4. Minor Site details revised at 1 of 16 sitesv103
  5. Minor Site details revised at 2 of 16 sitesv97
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose limiting toxicity (DLT) rate
Timeframe: Up to 28 days

Secondary (5)

Incidence of adverse events
Objective response rate
Progression free survival
Homologous recombination deficiency (HRD) status
Deoxyribonucleic acid damage repair activity

Arms and interventions

Treatment (peposertib, liposomal doxorubicin)Experimental

Patients receive peposertib PO BID on days 1-28 of each cycle and liposomal doxorubicin IV on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression, unacceptable toxicity or withdrawal of consent. Patients undergo blood sample collection and CT or MRI throughout the trial. Patients also undergo tissue biopsy and ECHO or MUGA during screening and on the trial.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan

Drugs: Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib

Sites

16 sites in 1 country